EA202092720A1 - Способ увеличения биологической доступности и степени воздействия активатора потенциалзависимых калиевых каналов - Google Patents
Способ увеличения биологической доступности и степени воздействия активатора потенциалзависимых калиевых каналовInfo
- Publication number
- EA202092720A1 EA202092720A1 EA202092720A EA202092720A EA202092720A1 EA 202092720 A1 EA202092720 A1 EA 202092720A1 EA 202092720 A EA202092720 A EA 202092720A EA 202092720 A EA202092720 A EA 202092720A EA 202092720 A1 EA202092720 A1 EA 202092720A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- potassium channel
- impact
- potential
- degree
- channel activator
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
В некоторых своих воплощениях данное изобретение относится к способам и применениям для лечения судорожных расстройств у человека, которые включают пероральное (например, во время или после еды) введение терапевтически эффективного количества аллостерического модулятора потенциалзависимых калиевых каналов, а именно N-[4-(6-фтор-3,4-дигидро-1Н-изохинолин-2-ил)-2,6-диметилфенил]-3,3-диметилбутанамида (соединения А) нуждающемуся в том индивиду. Данное описание относится также к различным усовершенствованным способам терапии и введения соединения А.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670253P | 2018-05-11 | 2018-05-11 | |
| PCT/US2019/031872 WO2019217924A1 (en) | 2018-05-11 | 2019-05-10 | Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202092720A1 true EA202092720A1 (ru) | 2021-04-14 |
Family
ID=66669101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202092720A EA202092720A1 (ru) | 2018-05-11 | 2019-05-10 | Способ увеличения биологической доступности и степени воздействия активатора потенциалзависимых калиевых каналов |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US11135214B2 (ru) |
| EP (2) | EP4279133A3 (ru) |
| JP (2) | JP7570924B2 (ru) |
| KR (1) | KR20210020892A (ru) |
| CN (1) | CN112384216A (ru) |
| AU (2) | AU2019265002C1 (ru) |
| BR (1) | BR112020022713A2 (ru) |
| CA (1) | CA3099292A1 (ru) |
| CL (1) | CL2020002932A1 (ru) |
| CO (1) | CO2020015476A2 (ru) |
| CR (1) | CR20200602A (ru) |
| DK (1) | DK3790548T3 (ru) |
| EA (1) | EA202092720A1 (ru) |
| ES (1) | ES2964409T3 (ru) |
| FI (1) | FI3790548T3 (ru) |
| GE (1) | GEP20237527B (ru) |
| HR (1) | HRP20231447T1 (ru) |
| HU (1) | HUE064326T2 (ru) |
| IL (1) | IL278577B1 (ru) |
| LT (1) | LT3790548T (ru) |
| MA (1) | MA52569B1 (ru) |
| MD (1) | MD3790548T2 (ru) |
| MX (2) | MX2020012008A (ru) |
| MY (1) | MY204915A (ru) |
| PE (1) | PE20211211A1 (ru) |
| PH (1) | PH12020551898A1 (ru) |
| PL (1) | PL3790548T3 (ru) |
| PT (1) | PT3790548T (ru) |
| RS (1) | RS64922B1 (ru) |
| SG (1) | SG11202011102TA (ru) |
| SI (1) | SI3790548T1 (ru) |
| SM (1) | SMT202300399T1 (ru) |
| UA (1) | UA127229C2 (ru) |
| WO (1) | WO2019217924A1 (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217924A1 (en) | 2018-05-11 | 2019-11-14 | Xenon Pharmaceuticals Inc. | Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener |
| TW202128627A (zh) | 2019-10-10 | 2021-08-01 | 加拿大商再諾製藥公司 | 選擇性鉀通道調節劑之固態晶型 |
| CR20220250A (es) | 2019-11-08 | 2022-08-19 | Xenon Pharmaceuticals Inc | Métodos para el tratamiento de trastornos depresivos |
| CN114786658A (zh) * | 2019-12-06 | 2022-07-22 | 泽农医药公司 | Kv7钾离子通道开放剂治疗疼痛的用途 |
| TW202245743A (zh) * | 2021-02-09 | 2022-12-01 | 加拿大商再諾製藥公司 | 治療癲癇症之聯合療法 |
| MX2023009314A (es) * | 2021-02-09 | 2023-08-16 | Xenon Pharmaceuticals Inc | Apertura del canal de potasio dependiente de voltaje para usarse en el tratamiento de la anhedonia. |
| CN113698345B (zh) * | 2021-10-27 | 2022-02-01 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的化合物及其制备和应用 |
| EP4074696A4 (en) * | 2021-10-27 | 2024-01-31 | Shanghai Zhimeng Biopharma, Inc. | Compound as potassium channel regulator, and preparation and use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8236861B2 (en) | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
| NZ563361A (en) | 2005-06-02 | 2011-02-25 | Schering Corp | HCV protease inhibitors in combination with food |
| CA2650853A1 (en) | 2006-05-02 | 2007-11-15 | Chris Rundfeldt | Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms |
| US8993593B2 (en) | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
| US8293911B2 (en) * | 2006-08-23 | 2012-10-23 | Valeant Pharmaceuticals International | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
| US20100323016A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
| US20120288544A1 (en) * | 2010-01-20 | 2012-11-15 | Glaxo Group Limited | Novel retigabine composition |
| US10500216B2 (en) | 2011-11-18 | 2019-12-10 | Corcept Therapeutics, Inc. | Optimizing mifepristone absorption |
| WO2019217924A1 (en) | 2018-05-11 | 2019-11-14 | Xenon Pharmaceuticals Inc. | Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener |
-
2019
- 2019-05-10 WO PCT/US2019/031872 patent/WO2019217924A1/en active Application Filing
- 2019-05-10 MA MA52569A patent/MA52569B1/fr unknown
- 2019-05-10 GE GEAP201915508A patent/GEP20237527B/en unknown
- 2019-05-10 IL IL278577A patent/IL278577B1/en unknown
- 2019-05-10 CA CA3099292A patent/CA3099292A1/en active Pending
- 2019-05-10 HU HUE19727216A patent/HUE064326T2/hu unknown
- 2019-05-10 EP EP23185386.2A patent/EP4279133A3/en active Pending
- 2019-05-10 FI FIEP19727216.4T patent/FI3790548T3/fi active
- 2019-05-10 PL PL19727216.4T patent/PL3790548T3/pl unknown
- 2019-05-10 UA UAA202007781A patent/UA127229C2/uk unknown
- 2019-05-10 SM SM20230399T patent/SMT202300399T1/it unknown
- 2019-05-10 LT LTEPPCT/US2019/031872T patent/LT3790548T/lt unknown
- 2019-05-10 MY MYPI2020005869A patent/MY204915A/en unknown
- 2019-05-10 EA EA202092720A patent/EA202092720A1/ru unknown
- 2019-05-10 DK DK19727216.4T patent/DK3790548T3/da active
- 2019-05-10 MX MX2020012008A patent/MX2020012008A/es unknown
- 2019-05-10 ES ES19727216T patent/ES2964409T3/es active Active
- 2019-05-10 HR HRP20231447TT patent/HRP20231447T1/hr unknown
- 2019-05-10 CN CN201980046273.0A patent/CN112384216A/zh active Pending
- 2019-05-10 AU AU2019265002A patent/AU2019265002C1/en active Active
- 2019-05-10 MD MDE20210233T patent/MD3790548T2/ro unknown
- 2019-05-10 JP JP2020562201A patent/JP7570924B2/ja active Active
- 2019-05-10 SI SI201930665T patent/SI3790548T1/sl unknown
- 2019-05-10 KR KR1020207035334A patent/KR20210020892A/ko active Pending
- 2019-05-10 RS RS20231089A patent/RS64922B1/sr unknown
- 2019-05-10 SG SG11202011102TA patent/SG11202011102TA/en unknown
- 2019-05-10 CR CR20200602A patent/CR20200602A/es unknown
- 2019-05-10 PT PT197272164T patent/PT3790548T/pt unknown
- 2019-05-10 BR BR112020022713-7A patent/BR112020022713A2/pt unknown
- 2019-05-10 EP EP19727216.4A patent/EP3790548B1/en active Active
- 2019-05-10 PE PE2020001843A patent/PE20211211A1/es unknown
- 2019-05-13 US US16/410,851 patent/US11135214B2/en active Active
-
2020
- 2020-11-09 PH PH12020551898A patent/PH12020551898A1/en unknown
- 2020-11-10 MX MX2023013247A patent/MX2023013247A/es unknown
- 2020-11-11 CL CL2020002932A patent/CL2020002932A1/es unknown
- 2020-12-11 CO CONC2020/0015476A patent/CO2020015476A2/es unknown
-
2021
- 2021-10-01 US US17/449,785 patent/US20220062266A1/en not_active Abandoned
-
2024
- 2024-04-26 US US18/648,049 patent/US20240316032A1/en active Pending
- 2024-05-30 US US18/679,045 patent/US20240316033A1/en active Pending
- 2024-09-17 AU AU2024219794A patent/AU2024219794A1/en active Pending
- 2024-10-09 JP JP2024177074A patent/JP2025011203A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202092720A1 (ru) | Способ увеличения биологической доступности и степени воздействия активатора потенциалзависимых калиевых каналов | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| MX2020007092A (es) | Metodos de uso de inhibidores ehmt2 para tratar o prevenir transtornos sanguineos. | |
| EA202091709A1 (ru) | Ингибиторы днк-пк | |
| EA200700333A1 (ru) | Терапевтические применения ингибиторов rtp801 | |
| EA202092086A1 (ru) | Ингибиторы аргиназы | |
| EA201991770A1 (ru) | Способ синтеза ингибитора индоламин-2,3-диоксигеназы | |
| MX2024002989A (es) | Formulaciones de 4-(7-hidroxi-2-isopropil-4-oxo-4h-quinazolin-3-il )-benzonitrilo. | |
| EA202091708A1 (ru) | Ингибиторы днк-пк | |
| CL2021002681A1 (es) | Inhibidores de la dihidroorotato deshidrogenasa. | |
| MX2023007212A (es) | Formulaciones de pulverizacion de epinefrina. | |
| EA202191122A1 (ru) | СЕЛЕКТИВНЫЕ К RGMc ИНГИБИТОРЫ И ИХ ПРИМЕНЕНИЕ | |
| EA202091559A1 (ru) | Способ получения модуляторов соматостатина | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| EA202192625A1 (ru) | Лиганды псевдокиназы tyk2 | |
| EA202191476A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA200601219A1 (ru) | Новые конденсированные пирролокарбазолы | |
| EA202091604A1 (ru) | Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом | |
| EA202193038A1 (ru) | Антитела против sema3a и их применения для лечения заболеваний глаз | |
| CO2022008001A2 (es) | Métodos para el tratamiento de trastornos depresivos | |
| MX2019002382A (es) | Anticuerpos anti-gremlin-1 (grem1) y metodos de uso de los mismos para tratar la hipertension arterial pulmonar. | |
| NO20055448L (no) | Kombinasjon av et analeptisk modafinil og en antidepressiv forbindelse for behandling av depresjon | |
| EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
| EA201990550A1 (ru) | Офтальмологический препарат, включающий азоловое соединение | |
| AR047716A1 (es) | Combinaciones de analepticos y antidepresivos |